This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hecht, D. W.
Right arrow Articles by Osmolski, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hecht, D. W.
Right arrow Articles by Osmolski, J. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2003, p. 910-916, Vol. 47, No. 3
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.3.910-916.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Activities of Garenoxacin (BMS-284756) and Other Agents against Anaerobic Clinical Isolates

David W. Hecht* and J. R. Osmolski

Hines VA Hospital, Hines, and Loyola University Medical Center, Maywood, Illinois

Received 28 March 2002/ Returned for modification 5 September 2002/ Accepted 20 November 2002

A total of 590 clinical isolates consisting of 33 species of both gram-positive and gram-negative anaerobes were collected from nine centers in the Chicago area in 1998-1999. The largest number of isolates (330 isolates, 56%) belonged to the Bacteroides group. Isolates were tested by agar dilution against garenoxacin (BMS-284756, T-3811 ME), trovafloxacin, moxifloxacin, clindamycin, imipenem, piperacillin-tazobactam, and cefoxitin. All but one species (2% of Bacteroides vulgatus isolates) were fully susceptible to piperacillin-tazobactam and imipenem. A number of species were resistant to clindamycin. Among the fluoroquinolones, garenoxacin and trovafloxacin had an MIC at which 90% of the isolates tested were inhibited of <4 µg/ml for all but two species (Fusobacterium mortiferum/varium and Peptostreptococcus anaerobius).

* Corresponding author. Mailing address: Loyola University Medical Center, 2160 S. First Ave., Maywood, IL 60153. Phone: (708) 216-3232. Fax: (708) 216-8198. E-mail: dhecht{at}lumc.edu.

Antimicrobial Agents and Chemotherapy, March 2003, p. 910-916, Vol. 47, No. 3
0066-4804/03/$08.00+0     DOI: 10.1128/AAC.47.3.910-916.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Kononen, E., Bryk, A., Niemi, P., Kanervo-Nordstrom, A. (2007). Antimicrobial Susceptibilities of Peptostreptococcus anaerobius and the Newly Described Peptostreptococcus stomatis Isolated from Various Human Sources. Antimicrob. Agents Chemother. 51: 2205-2207 [Abstract] [Full Text]  
  • Krishna, G., Kisicki, J. C., Olsen, S., Grasela, D. M., Wang, Z. (2007). The Effect of Omeprazole on the Bioavailability and Safety of Garenoxacin in Healthy Volunteers. J Clin Pharmacol 47: 628-632 [Abstract] [Full Text]  
  • Edmiston, C. E. Jr, Krepel, C. J., Kehl, K. S., Seabrook, G. R., Somberg, L. B., Almassi, G. H., Smith, T. L., Loehrl, T. A., Brown, K. R., Lewis, B. D., Towne, J. B. (2005). Comparative in vitro antimicrobial activity of a novel quinolone, garenoxacin, against aerobic and anaerobic microbial isolates recovered from general, vascular, cardiothoracic and otolaryngologic surgical patients. J Antimicrob Chemother 56: 872-878 [Abstract] [Full Text]  
  • Conrads, G., Citron, D. M., Goldstein, E. J. C. (2005). Genetic Determinant of Intrinsic Quinolone Resistance in Fusobacterium canifelinum. Antimicrob. Agents Chemother. 49: 434-437 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»